IMCR250117P85000
- 0.00
- 0.000.00%
Immunocore Newsroom
Needham Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $71
Immunocore Holdings Positioned for Growth With Strategic 2025 Priorities and Strong Financial Outlook
Immunocore Reports Cash, Equivalents of $820M as of December 31
Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer
Immunocore to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Immunocore Names Non-Executive Board Member as CFO
Immunocore Names Travis Coy Chief Financial Officer
Express News | Immunocore Appoints Travis Coy, Previously a Non-Executive Director, as Its Evp, Chief Financial Officer and Head of Corporate Development
Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Express News | Immunocore Announces First Patient Dosed in the Phase 1 Trial of Imc-P115C, a Half-Life Extended (Hle) Immtac Candidate in Patients With Tumors That Express Prame
Jefferies Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $45
Express News | Immunocore Begins Phase 1/2 Trial of IMC-R117C, The First Immunotherapy Targeting PIWIL1 In Advanced Gastrointestinal Cancers
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley Downgrades Immunocore Holdings to Equalweight From Overweight, Cuts Price Target to $35 From $74
Morgan Stanley Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $35
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Immunocore Enrolls First Patient in Phase 3 Uveal Melanoma Trial